Page last updated: 2024-10-24

insulin catabolic process

Definition

Target type: biologicalprocess

The chemical reactions and pathways resulting in the breakdown of insulin. [GOC:TermGenie]

Insulin catabolism is a complex process that involves the breakdown of insulin molecules into smaller fragments, ultimately rendering the hormone inactive. This process is essential for maintaining proper blood glucose levels and preventing insulin-induced hypoglycemia. The primary sites of insulin catabolism are the liver and kidneys, although other tissues like the brain and muscles also contribute to a lesser extent.

Insulin degradation commences with the binding of insulin to its receptor on the surface of target cells. This binding triggers internalization of the insulin-receptor complex, leading to its delivery to lysosomes, the cellular organelles responsible for breaking down waste products.

Within lysosomes, a variety of proteases, primarily insulin-degrading enzyme (IDE), cleave the insulin molecule at specific peptide bonds. IDE is a zinc-dependent metalloprotease known to be the primary enzyme responsible for insulin degradation. It cleaves insulin at the A-chain, generating an N-terminal fragment and a C-terminal fragment.

Other proteases, such as cathepsins and elastase, may also contribute to insulin degradation. These enzymes, often located in lysosomes, can cleave insulin at various sites, further breaking down the insulin fragments generated by IDE.

The products of insulin catabolism, the smaller peptides and amino acids, are then either reused by the cell or excreted. This ensures that insulin's biological activity is terminated and that the body's glucose homeostasis is maintained.

Factors affecting insulin catabolism include blood glucose levels, insulin concentrations, and the presence of insulin antibodies. Elevated blood glucose levels increase insulin catabolism, while high insulin levels promote its degradation. Insulin antibodies can interfere with insulin degradation, prolonging the hormone's action.

Insulin catabolism plays a critical role in regulating blood glucose levels and is crucial for maintaining proper metabolic function. Disruptions in this process, as seen in certain disease states, can lead to insulin resistance and hyperglycemia, ultimately increasing the risk for diabetes and other metabolic disorders.'
"

Proteins (2)

ProteinDefinitionTaxonomy
Insulin-degrading enzymeAn insulin-degrading enzyme that is encoded in the genome of human. [PRO:DNx, UniProtKB:P14735]Homo sapiens (human)
Cathepsin DA cathepsin D that is encoded in the genome of human. [PRO:DNx, UniProtKB:P07339]Homo sapiens (human)

Compounds (25)

CompoundDefinitionClassesRoles
ebselenebselen : A benzoselenazole that is 1,2-benzoselenazol-3-one carrying an additional phenyl substituent at position 2. Acts as a mimic of glutathione peroxidase.benzoselenazoleanti-inflammatory drug;
antibacterial agent;
anticoronaviral agent;
antifungal agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
EC 1.3.1.8 [acyl-CoA dehydrogenase (NADP(+))] inhibitor;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitor;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
EC 3.1.3.25 (inositol-phosphate phosphatase) inhibitor;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
EC 3.5.4.1 (cytosine deaminase) inhibitor;
EC 5.1.3.2 (UDP-glucose 4-epimerase) inhibitor;
enzyme mimic;
ferroptosis inhibitor;
genotoxin;
hepatoprotective agent;
neuroprotective agent;
radical scavenger
nafamostatnafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplasticbenzoic acids;
guanidines
rabeprazoleRabeprazole: A 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.benzimidazoles;
pyridines;
sulfoxide
anti-ulcer drug;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor
1,2-diphenylhydrazine
cefmetazolecefmetazole : A second-generation cephalosporin antibiotic having N(1)-methyltetrazol-5-ylthiomethyl, {[(cyanomethyl)sulfanyl]acetyl}amino and methoxy side-groups at positions 3, 7beta and 7alpha respectively of the parent cephem bicyclic structure.

Cefmetazole: A semisynthetic cephamycin antibiotic with a broad spectrum of activity against both gram-positive and gram-negative microorganisms. It has a high rate of efficacy in many types of infection and to date no severe side effects have been noted.
cephalosporinantibacterial drug
amprenavircarbamate ester;
sulfonamide;
tetrahydrofuryl ester
antiviral drug;
HIV protease inhibitor
bila 2157 bsBILA 2157 BS: renin inhibitor; RN given for (1S-(1R*(S*),2S*,3R*))-isomer; structure in first source
resveratroltrans-resveratrol : A resveratrol in which the double bond has E configuration.resveratrolantioxidant;
phytoalexin;
plant metabolite;
quorum sensing inhibitor;
radical scavenger
om99-2OM99-2: eight-residue memapsin 2 inhibitor; structure in first source
pl 100PL 100: inhibits HIV-1 protease; structure in first source
myricetin7-hydroxyflavonol;
hexahydroxyflavone
antineoplastic agent;
antioxidant;
cyclooxygenase 1 inhibitor;
food component;
geroprotector;
hypoglycemic agent;
plant metabolite
benzyloxycarbonyl-phe-ala-fluormethylketonecathepsin B inhibitor : A cysteine protease inhibitor which inhibits cathepsin B (EC 3.4.22.1).
pepstatinpepstatin: inhibits the aspartic protease endothiapepsinpentapeptide;
secondary carboxamide
bacterial metabolite;
EC 3.4.23.* (aspartic endopeptidase) inhibitor
ca 074
kni 10006
balicatibbalicatib: cathepsin K inhibitor
tasiamide btasiamide B: 4-amino-3-hydroxy-5-phenylpentanoic acid containing peptide from the marine cyanobacterium Symploca sp.; structure in first source
calpain inhibitor iiicalpain inhibitor III: potential anticataract drug
PF-00835231PF-00835231 : A primary alcohol resulting from the cleavage of the phosphate group of the prodrug PF-07304814. It is an inhibitor of SARS-CoV-1 and -2 main protease (3CLpro) and exhibits potent in vitro antiviral activity.aromatic ether;
indolecarboxamide;
L-leucine derivative;
primary alcohol;
pyrrolidin-2-ones;
secondary carboxamide
anticoronaviral agent;
drug metabolite;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor
gsk188909GSK188909: a potent and selective non-peptidic BACE-1 inhibitor; structure in first source
ly2811376
grassystatin agrassystatin A: isolated from a cyanobacterium, identified as Lyngbya cf.; structure in first source
ly2886721
tipranavirtipranavir : A pyridine-2-sulfonamide substituted at C-5 by a trifluoromethyl group and at the sulfonamide nitrogen by a dihydropyrone-containing m-tolyl substituent. It is an HIV-1 protease inhibitor.

tipranavir: inhibits HIV-1 protease
sulfonamideantiviral drug;
HIV protease inhibitor
rolitetracyclinerolitetracycline : A derivative of tetracycline in which the amide function is substituted with a pyrrolidinomethyl group.

Rolitetracycline: A pyrrolidinylmethyl TETRACYCLINE.